| 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-026 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 第三届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见公司在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）发布的《2023 年年度报告全文及其摘要》。 本议案已经公司审计委员会审议通过。 表决结果：同意 7 票；反对 0 票；弃权 0 票。 本议案尚需提交公司 2023 年年度股东大会表决。 2、审议通过《2024 年第一季度报告全文》 浙江泰林生物技术股份有限公司（以下简称"公司"）第三届董事会第二十 四次会议于 2024 年 4 月 12 日以电话、书面送达等形式发出通知，并于 4 月 23 日在公司会议室以现场举手表决的方式召开。会议应出席董事 7 名，实际出席董 事 7 名。本次会议由叶大林先生召集和主持，公司董事会秘书、监事及高管列席 会议。 ...

浙江泰林生物技术股份有限公司 独立董事候选人声明与承诺 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规定的独立董事任职资格和条件。 声明人杨忠智作为浙江泰林生物技术股份有限公司第四届董事会独立董 事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立性 的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一、本人已经通过浙江泰林生物技术股份有限公司第三届董事会提名委员 会资格审查，提名人与本人不存在利害关系或者可能妨碍本人独立履职的其他 关系。 是 □ 否 是 □ 否 如否，请详细说明：______________________________ 四、本人符合该公司章程规定的独立董事任职条件。 是 □ 否 如否，请详细 ...

Financial Performance - The company's operating revenue for 2023 was ¥269,856,059.81, a decrease of 27.82% compared to ¥373,878,114.24 in 2022[23]. - The net profit attributable to shareholders for 2023 was ¥19,668,950.46, down 75.32% from ¥79,686,202.54 in 2022[23]. - The cash flow from operating activities for 2023 was ¥1,931,884.51, a significant decline of 97.84% from ¥89,385,619.71 in 2022[23]. - The basic earnings per share for 2023 was ¥0.18, a decrease of 75.68% compared to ¥0.74 in 2022[23]. - Total revenue for 2023 was ¥269,856,059.81, a decrease of 27.82% compared to ¥373,878,114.24 in 2022[81]. - Revenue from the pharmaceutical industry accounted for 87.57% of total revenue, totaling ¥236,320,827.02, down 31.50% from ¥344,999,759.36 in 2022[82]. - Revenue from other industries increased by 16.13%, reaching ¥33,535,232.79, compared to ¥28,878,354.88 in 2022[82]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which was ¥11,236,498.92 in 2023, down 84.55% from ¥72,716,619.21 in 2022[23]. Cost and Profitability - The gross profit margin for various product lines decreased due to fluctuations in sales prices, raw material costs, and rising labor costs[3]. - Sales expenses increased year-on-year due to active market expansion efforts, including exhibitions and promotional activities[3]. - The sales volume of the sterile production and contamination control equipment series products decreased by 52.26% year-over-year, while inventory increased by 66.78% due to extended delivery cycles requested by some customers[87]. - The pharmaceutical industry generated revenue of ¥236,320,827, with a gross margin of 45.75%, reflecting a year-over-year revenue decrease of 31.50% and a gross margin decline of 4.59%[84]. - The microbiological testing technology series products achieved revenue of ¥106,356,623, with a gross margin of 52.89%, showing a revenue decline of 7.52% compared to the previous year[84]. Research and Development - The company plans to accelerate the development and launch of new products, including radioactive drug production equipment and new quality control strains, to cultivate new growth points[5]. - The company is focusing on the research and development of specialized instruments and consumables for new drug development and quality control[32]. - The company has established a comprehensive R&D system, including partnerships with renowned institutions like the Military Medical Academy and Zhejiang University, to drive technological advancements[48]. - The company has invested over 10% of its sales revenue annually into technology research and new product development[54]. - The company’s R&D investment amounted to ¥58,403,826.62 in 2023, representing 21.64% of operating revenue, an increase from 17.24% in 2022[100]. Market Strategy and Expansion - The company aims to enhance production efficiency and reduce costs through process innovation and automation upgrades[5]. - Future plans include focusing on key projects aligned with national development goals, such as biomanufacturing and water safety assurance projects[4]. - The company is actively pursuing market expansion in the pharmaceutical, food, and environmental sectors through innovative product offerings[94]. - The marketing strategy will combine direct sales and distribution channels to increase overseas market share[131]. - The company plans to enhance R&D investment, particularly in high-end talent and international patent applications, to gain competitive advantages[129]. Corporate Governance and Management - The company has established a performance evaluation incentive system linking management compensation to business performance[144]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[143]. - The company has implemented a stock incentive plan for 2022, which includes a first-time grant of stock options[149]. - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finances[145]. - The company has established a risk management and internal control organization to supervise and evaluate internal controls[192]. Environmental and Social Responsibility - The company has implemented measures to prevent pollution, including wastewater treatment and air emission controls[198]. - The company has established an emergency response plan for environmental incidents, ensuring preparedness for potential accidents[199]. - The company promotes a corporate culture focused on innovation and social responsibility[200]. - The company emphasizes a balance between economic and social benefits, aiming for sustainable development[200]. - The company has a comprehensive waste management strategy, including the disposal of hazardous materials by certified services[198]. Shareholder Returns - A cash dividend of 1 RMB per 10 shares (including tax) will be distributed to all shareholders, with no bonus shares issued[6]. - The cash dividend represents 100% of the total distributable profit of 141,597,733.79 CNY[183]. - The cash dividend distribution was completed on May 10, 2023, following the approval of the shareholders' meeting[181]. - The company plans to distribute a cash dividend of 3 CNY (including tax) for every 10 shares, totaling 10,871,593.10 CNY based on a total share capital of 108,715,931 shares[181]. Talent Management - The company has established a differentiated compensation system based on different levels and positions, including basic salary, allowances, and performance bonuses[177]. - The company is committed to building a comprehensive talent training system, focusing on professional skills, management enhancement, and general education[178]. - The total number of employees at the end of the reporting period is 888, with 51 from the parent company and 837 from major subsidiaries[176]. - The company has set up Tai Lin Academy to incentivize learning and reward proactive learners[178]. - The company emphasizes the importance of adapting salary levels based on inflation and industry salary trends[177].

Revenue and Profitability - The company's revenue for Q1 2024 was ¥80,006,616.11, representing a 1.34% increase compared to ¥78,946,553.19 in the same period last year[4] - Net profit attributable to shareholders decreased by 66.58% to ¥5,873,080.66 from ¥17,575,025.59 year-on-year[4] - Basic earnings per share dropped by 76.19% to ¥0.05 from ¥0.21 in the same period last year[4] - The operating profit for Q1 2024 was CNY 5,839,769.83, down 67.7% from CNY 18,061,319.64 in Q1 2023[16] - The company’s total profit for Q1 2024 was CNY 5,915,782.07, down 67.4% from CNY 18,119,742.81 in Q1 2023[16] - Total revenue from sales of goods and services was CNY 69,307,264.31, slightly down from CNY 70,164,007.52 year-over-year[19] Cash Flow and Financial Position - The net cash flow from operating activities improved by 64.64%, reaching -¥6,296,392.84 compared to -¥17,807,115.09 in the previous year[4] - The company reported a significant increase of 784.97% in cash received from investment activities, totaling ¥176,994,526.02 compared to ¥20,000,000.00 in the previous year[8] - The net cash flow from operating activities was negative CNY 6,296,392.84, an improvement from negative CNY 17,807,115.09 in the previous year[20] - The company recorded cash inflow from investment activities of CNY 176,994,526.02, significantly higher than CNY 20,021,328.30 in the same period last year[20] Assets and Liabilities - Total assets decreased by 3.04% to ¥943,881,120.62 from ¥973,507,907.87 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2024 were CNY 381,299,872.13, down 3.99% from CNY 396,982,503.20 at the beginning of the quarter[12] - Accounts receivable decreased to CNY 30,667,162.32, a decline of 15.00% from CNY 36,082,237.96 at the start of the quarter[12] - Total current assets amounted to CNY 610,612,858.58, down 4.40% from CNY 638,750,200.42 at the beginning of the quarter[13] - Total liabilities decreased to CNY 288,045,720.37, a reduction of 10.92% from CNY 323,268,730.54 at the end of the previous quarter[14] - Total equity attributable to shareholders increased to CNY 654,691,034.97, up from CNY 648,762,936.31 at the end of the previous quarter[14] Expenses and Financial Performance - Total operating costs for Q1 2024 were CNY 77,318,177.90, up 19.00% from CNY 64,924,390.99 in the same period last year[15] - Research and development expenses increased to CNY 14,896,419.24, reflecting a rise of 6.80% from CNY 13,945,439.84 in Q1 2023[15] - The company’s financial expenses surged by 122.25% to ¥659,825.50 due to the capitalization of convertible bond interest expenses[8] - The company experienced a decrease in financial expenses, reporting CNY 659,825.50, compared to a loss of CNY 2,965,848.16 in the previous year[16] - The company’s tax expenses for Q1 2024 were CNY 374,577.16, a decrease from CNY 544,717.22 in the same period last year[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,529, with the largest shareholder holding 53.19% of the shares[10] - The company received government subsidies amounting to ¥279,310.38 during the reporting period[7] Other Financial Metrics - The company’s weighted average return on equity decreased to 0.90% from 2.68% in the previous year[4] - Inventory at the end of Q1 2024 was CNY 150,289,218.55, down 6.45% from CNY 160,550,413.98 at the beginning of the quarter[12] - The company reported a net profit margin improvement, although specific figures were not disclosed in the provided content[15]

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-031 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 1. 首次公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准浙江泰林生物技术股份有限公司首次 公开发行股票的批复》（证监许可〔2019〕2962 号）核准，并经深圳证券交易所 同意，本公司由主承销商安信证券股份有限公司采用余额包销方式，向社会公众 公开发行人民币普通股（A 股）股票 1,300.00 万股，发行价为每股人民币 18.35 元，共计募集资金 23,855.00 万元，坐扣承销和保荐费用 2,545.00 万元后的募 集资金为 21,310.00 万元，已由主承销商安信证券股份有限公司于 2020 年 1 月 9 日汇入本公司募集资金监管账户。另减除上网发行费、招股说明书印刷费、申 报会计师费、律师费、评估费等与发行权益性证券直接相关的新增外部费用 1,516.45 万元（不含税）后，公司本次募集资金净额为 19,793.55 万元。上述 募集资金到位情况业 ...

2023 年，浙江泰林生物技术股份有限公司（以下简称"公司"）董事会严格 按照《公司法》《证券法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法 规、规范性文件及《公司章程》的相关规定，认真履行董事会职能，勤勉尽责的 开展各项工作，推动公司规范运作及各项业务有序开展，现将公司董事会 2023 年工作情况汇报如下： 浙江泰林生物技术股份有限公司 2023 年度董事会工作报告 报告期内，公司董事会共召开董事会 11 次，对提交董事会的 44 项议案进行 了审议，所有议案均获通过。具体如下： | | 2023 年 | 2022 年 | 本年比上年增减 | 2021 年 | | --- | --- | --- | --- | --- | | 营业收入（元） | 269,856,059.81 | 373,878,114.24 | -27.82% | 283,248,491.21 | | 归属于上市公司股 | 19,668,950.46 | 79,686,202.54 | -75.32% | 63,529,851.10 | | 东的净利润（元） ...

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-037 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 关于提请股东大会授权董事会办理以简易程序向特定对象 发行 A 股股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）于2024年4月23日召 开了第三届董事会第二十四次会议，审议通过了《关于提请股东大会授权董事会 办理以简易程序向特定对象发行A股股票的议案》，同意公司董事会提请股东大 会授权董事会向特定对象发行融资总额不超过人民币3亿元且不超过最近一年末 净资产20%的股票，授权期限为2023年年度股东大会通过之日起至下一年度股东 大会召开之日止。本次授权事宜尚需提请公司2023年年度股东大会审议。现将有 关情况公告如下： 一、具体内容 （一）拟发行证券的种类和数量 发行股票募集资金总额不超过人民币3亿元且不超过最近一年末净资产的 20%。发行股票的种类为境内上市人民币普通股（A股），每股面值人民币1.00 元 ...

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-034 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）第三届董事会任期已 届满，根据《中华人民共和国公司法》等法律法规、规范性文件及《公司章程》 等有关规定，公司决定按照相关法律程序进行董事会换届选举，并于 2024 年 4 月 23 日召开第三届董事会第二十四次会议，审议通过了《关于提请选举公司第 四届董事会非独立董事的议案》《关于提请选举公司第四届董事会独立董事的议 案》等议案。公司董事会同意提名叶大林先生、沈志林先生、夏信群先生、倪小 璐先生为第四届董事会非独立董事候选人；同意提名杨忠智先生、董明先生、倪 崖先生为第四届董事会独立董事候选人（上述候选人简历详见附件）。 董事会提名委员会对上述董事候选人的任职资格进行了审查，上述候选人符 合《中华人民共和国公司法》《公司章程》等规定的任职条件。上 ...

浙江泰林生物技术股份有限公司 （三）现金流情况 单位：元 | 项目 | 2023 年 | 2022 年 | 同比增减 | | | --- | --- | --- | --- | --- | | 经营活动现金流入小计 | 348,325,147.14 | 407,616,548.79 | | -14.55% | | 经营活动现金流出小计 | 346,393,262.63 | 318,230,929.08 | | 8.85% | | 经营活动产生的现金流 | 1,931,884.51 | 89,385,619.71 | | -97.84% | | 量净额 | | | | | | 投资活动现金流入小计 | 397,897,984.80 | 284,773,910.81 | | 39.72% | 单位：元 项目 2023 年 2022 年 本年比上年增减 总资产 973,507,907.87 922,660,005.83 5.51% 总负债 323,268,730.54 275,205,185.78 17.46% 归属于上市公司股东的净资产 648,762,936.31 647,454,820.05 0.20% 单位 ...

浙江泰林生物技术股份有限公司 独立董事 2023 年度述职报告 作为浙江泰林生物技术股份有限公司（以下简称"公司"）的独立董事，2023 年本人严格按照《公司法》《上市公司独立董事管理办法》《公司独立董事工作制 度》以及《公司章程》等有关法律法规的规定和要求，忠实履行职责，及时出席 相关会议，认真审议董事会各项议案，充分发挥了独立董事及各专业委员会的作 用，切实维护了公司整体利益和全体股东尤其是中小股东的合法权益。现将 2023 年的工作情况简要汇报如下： 一、个人基本情况 本人董明，于 1999 年毕业于浙江大学生物医学工程专业，工学硕士学位， 1983 年 8 月至 2020 年 3 月在浙江医院工作，历任器械科助理工程师、工程师， 工程科高级工程师、副科长、科长，工程部副主任、高级工程师。目前已退休。 现任浙江泰林生物技术股份有限公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席董事会及股东大会情况 （三）独立董事专门会议工作情况及独立意见发表情况 根据中国证监会《上市公司独立董事管理办法》等相关规定以及结合 ...